Essay On Proton Pump Inhibitors

Chapter One: Introduction

Proton pump inhibitors were initially introduced in 1980 and are widely used for the management of gastric acid conditions such as gastric ulcers, duodenal, reflux oesophagitis, and gastroesophageal reflux disease. Proton pump inhibitors decrease the acid production by enzyme blocking within the stomach walls that produce acids. Acid plays a major role in the production of oesophagus, stomach, duodenum ulcers. Proton pump inhibitors are responsible for the reduction of acid as it works on preventing ulcers and heal all types of ulcers present in stomach, duodenum, and oesophagus. Proton pump inhibitors are widely used method of medication in UK and US (Toh, 2014).

The reason for proton pump inhibitors’ frequent usage is its ability to potently suppress gastric acids. Proton pump inhibitors (PPI) are also considered better than alternatives like histamine-2 receptor antagonists (H2RAs) and are used for common gastric acid-related problems, such as peptic ulcer disease, and gastroesophageal reflux disease (GERD). Due to their effectiveness, PPI are commonly suggested as the first-line

conducted this research, in 2015 understanding the effect of Hypomagnesaemia after long-term treatment with Proton pump inhibitors. Hypomagnesaemia was initially described as a complication after usage of Proton pump inhibitors in 2006. To address this issue, literature was reviews as a method of this research using secondary data collection method. It was observed that Hypomagnesaemia was mostly reported to increase chances of hypoparathyroidism, hypokalemia, and hypocalcemic as mentioned by 64 individuals on long-term treatment of PPI. It was obtained from another study that Hypomagnesaemia recurred with replacement of PPI with another. However, this was not with the case of histamine type-2 receptor antagonists. In another cross sectional study, connection between magnesium metabolism and proton pump inhibitors were also mentioned in 14